BioNTech reports unbelievable YoY growth for its fiscal Q4

BioNTech SE shares (NASDAQ: BNTX) opened 8% up on Wednesday after the pharmaceutical company handily beat Street expectations for Q4 earnings and revenue.

Notable figures in BioNTech Q4 earnings report

Net profit printed at €3.17 billion ($3.51 billion), compared to last year’s €3.66 million.
Operating income of €4.70 billion noted a significant YoY growth from €244 million.
Revenue soared to €5.53 billion versus the year-ago figure of only €345 million.
Announced plans of repurchasing $1.50 billion worth of its stock over the next two years.
BioNTech will propose €2.0 a share of special cash dividend at its annual general meeting.

Comirnaty sales outlook for 2022

According to the earnings press release, in 2021, BioNTech delivered 2.6 billion doses of Comirnaty – its COVID shot that it developed in collaboration with Pfizer.

New vaccine orders now stand at 2.4 billion doses for 2022. The German firm expects up to €17 billion in revenue from Comirnaty this year. This, however, compares to an even higher €17.59 billion that analysts anticipate.

Nonetheless, the boost from COVID vaccine sales will see BioNTech spend roughly €1.50 billion on R&D in 2022; about a 50% increase from what was indicated previously. Other than COVID-19, R&D will also focus on oncology and infectious diseases.

A day earlier, CDC recommended fourth dose of Comirnaty for people aged fifty and above.

The post BioNTech reports unbelievable YoY growth for its fiscal Q4 appeared first on Invezz.

Disclaimer:, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2022 All Rights Reserved.

To Top